Inclusion criteria This review considered peer-reviewed studies of L-carnitine supplementation in subjects with coronary artery disease across predefined designs, each with a distinct role, including preclinical evidence such as animal studies which provided mechanistic evidence and insights on emerging pathways, as well as clinical evidence such as case reports, cross-sectional studies, observational studies, retrospective analyses, randomized controlled trials, systematic review and meta-analyses which provided primary evidence as well as quantitative analysis of clinical endpoints
the preferred embodiment includes the variations of the amount of glutathione to create less concentrated amounts of glutathione
The FDA has given the green light for its use in many types of patients
From the laboratory of Jin Wang, PhD, Baylor College of Medicine
Information and statements on this site have not been evaluated by the Food and Drug Administration.
Acknowledgements Nicola Guess was funded by a Diabetes UK Allied Health Professional Fellowship
